Pharma titan George W. Merck ran the Pentagon’s offensive bioweapons program while simultaneously directing his drug manufacturing behemoth. Merck boasted that his team could deliver biowarfare agents without vast expenditures or constructing huge facilities. Another advantage of bioweapons, he remarked, was that their development could proceed under the guise of legitimate medical research.
